w10.0.13 | c2.0.0.8
PROD | u7.5.14
  Quick Order  0
 

Quick Order

X

EVOcard

Oligonucleotide Synthesis

Gene Synthesis & Molecular Biology

Sanger Sequencing

Next Generation Sequencing

Genotyping & Gene Expression

Header Image service-corner
 

 

print content
increase font
decrease font

Eurofins Genomics Pressemitteilungen

Additional Information

Kontakt

Für weitere Informationen kontaktieren Sie bitte das Marketing Communications Team: pr-eu@eurofins.com

Adobe Acrobat Reader

Wenn Sie PDF-Dateien nicht lesen können, laden Sie sich bitte den Acrobat Reader herunter.

 

 
08/03/2022 Ebersberg, Deutschland
 
Eurofins Genomics is proud to announce its support for Our Future Health, the UK’s largest ever health research programme. Eurofins Genomics will be genotyping five million consenting participants within Our Future Health. This will provide important data that, when combined with other questionnaire and health information, will generate a comprehensive picture of population health in the UK, insights from which will be used to transform the prevention, detection and treatment of diseases. [download]
18/05/2021 Ebersberg, Deutschland
 
Eurofins Genomics Europe, a leader in genomic products and services, is further expanding its SARS-CoV-2 full genome sequencing capacity. The laboratory in Constance, Germany, has sequenced more than 100,000 SARS-CoV-2 samples from 23 countries in the past three months. Eurofins Genomics Europe’s “ARTIC SARS-CoV-2 Whole Genome Sequencing” service includes next-generation sequencing (NGS) and detailed reporting for universal end-to-end surveillance of pandemic development, tracking the emergence and dynamics of existing and new mutational Variants of Concern. [download]
03/03/2021 Ebersberg, Deutschland
 
Eurofins Genomics has provided RNA sequencing for researchers of the IMI2 INNODIA consortium and the data has been published in the prestigious life science journals Cells and Nature. [download]
28/02/2021 Ebersberg, Deutschland
 
Eurofins Genomics is proud to donate on behalf of the Eurofins Foundation to the NCL Foundation’s research project “Dissecting the CLN3 function”. It has been found that Batten disease in children is linked to a mutated CLN3 gene. The provided funding supports the development of a CLN3 assay for a proposal at the National Center for Advancing Translational Sciences (NCATS). This would form the basis to implement an approved diagnostics tool for Battens disease. To achieve that, the charity organization is now able to create a PhD position that focuses exclusively on the research of the Battens disease. Dr. Emyr Lloyd-Evans will oversee the research and the newly created position will be part of his team. [download]
23/02/2021 Ebersberg, Deutschland
 
The European Centre for Disease Prevention and Control (ECDC) has begun work with Eurofins Genomics with the objective to monitor mutations across European countries. The EU/EEA Member States are in the phase of increasing both their sequencing capacities and capabilities to set up a robust surveillance system that allows for the detection and monitoring of variant viruses. To support this goal, Eurofins Genomics will provide additional sequencing capacity by using the ARTIC Next Generation Sequencing (NGS) technology with a rapid turn-around time including bioinformatic services and volume of thousands of samples per week. [download]
15/02/2021 Ebersberg, Deutschland
 
The work on producing genotype data for the population-based longitudinal cohorts in SIMPLER, a Swedish national research infrastructure hosted by Uppsala University, has been finalised and the project coordinator in SIMPLER describes the collaboration with Eurofins Genomics as very successful. [download]
16/04/2020 Ebersberg, Deutschland
 
Eurofins Genomics Europe, a leader in genomic products and services, announces the launch of its “SARS-CoV-2 Full-length Genome Sequencing” service, a new next generation sequencing (NGS) service enabling end-to-end surveillance of the coronavirus genome sequence and mutational drift. The new service is Eurofins Genomics’ latest addition to a whole product portfolio aimed at supporting researchers globally in their fight against the COVID-19 pandemic. [download]
13/11/2019 Ebersberg, Deutschland
 
Eurofins Genomics has just launched a next generation sequencing (NGS) service that enables customers to analyse mutations introduced by the CRISPR/Cas9 system. This new service delivers highly reliable results with the most complete coverage, quickly and conveniently. [download]
23/10/2019 Ebersberg, Deutschland
 
Eurofins Genomics, the international provider of genomics services, has made a donation to ‘Ärzte ohne Grenzen / Médecins Sans Frontières’, a humanitarian medical organisation that provides medical aid in conflict zones and countries stricken by endemic diseases around the world. [download]
16/10/2019 Ebersberg, Deutschland
 
Eurofins Genomics helps uncover a groundbreaking link between ovarian cancer and the microbiome. As part of one of the first reports of its kind, Eurofins Genomics was a research partner in a project funded by EU Horizon 2020 and Eve Appeal. The results of the research showed that in women at risk of developing ovarian cancer, or those who may already have ovarian cancer, had a significantly decreased amount of “good” lactobacilli bacteria present in their microbiome. These results could have a significant impact on how ovarian cancer risk may be reduced in the future. [download]
10/03/2016
 
Agilent Technologies Inc. (NYSE: A) and Eurofins Genomics today announced that Agilent plans to offer custom components and an assembled plasmid service for Agilent's SureVector next-generation cloning kits through a collaboration with Eurofins. Agilent will also offer a set of catalog components for its leading-edge SureVector cloning kits, enabling the creation of over 1 million different cloning vectors. [read more]
01/03/2016
 
Eurofins Scientific (EUFI.PA), the global leader in bio-analytical testing, and one of the world leaders in genomic services, announces the opening of its new state-of-the-art manufacturing and services facility in Louisville, KY, in the US. The large, 65,800 ft2 (6,113 m2) facility functions as the Group’s central genomics laboratory in North America, focusing on the custom production of DNA and RNA oligonucleotides synthetic gene synthesis, and genomics services including DNA sequencing, synthetic biology, and next generation sequencing (NGS). [read more]
07/01/2016
 
Eurofins Scientific (EUFI.PA), one of the world leaders in genomic services, and Weatherbys Ireland DNA Laboratories, one of Europe’s leading animal genomic laboratories, are pleased to announce that they have been jointly selected to test one million samples of beef for the Irish Cattle Breeding Federation (ICBF) over the next two years. [read more]
16/12/2015 Ebersberg
 
Gebündelte Expertise und neueste Technologien für Dienstleistungen in der Molekularbiologie und DNA Analyse. [read more]
06/10/2015 Aarhus, Denmark
 
Certification underlines AROS’ strength for NGS services within the regulatory field. [read more]
01/10/2015 Ebersberg, Deutschland
 
Eurofins Genomics und tilibit nanosystems schließen eine globale Vertriebsvereinbarung. [read more]
27/08/2015 Ebersberg, Germany
 
Next generation sequencing techniques for microbiome profiling of food, pharma and environmental samples dedicated to industrials and academic services. [read more]
03/06/2015 Ebersberg, Deutschland
 
Eurofins Genomics und das Institut für Bienenkunde Hohen Neuendorf e.V. sind Partner im Rahmen des Programms „Forschung für Innovation in der Agrarwirtschaft“. [download]
20/05/2015 Ebersberg, Germany
 
Custom cGMP services with highly standardised process controls that meet customer requirements. [read more]
12/11/2014 Ebersberg, Germany
 
GLP accreditation offering the highest quality services to all customers. [read more]